On June 13, 2025, Sage Therapeutics, Inc. announced a merger agreement with Supernus Pharmaceuticals, where shareholders will receive $8.50 per share plus contingent value rights potentially worth an additional $3.50, contingent on achieving certain
AI Assistant
SAGE THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.